> News
 > Everimmune launches Phase I clinical trial for its oncobiotic drug candidate in lung and kidney cancer
News
16/01/2023

Everimmune launches Phase I clinical trial for its oncobiotic drug candidate in lung and kidney cancer

Villejuif-Grand Paris, France, January 16, 2023 – EverImmune, a clinical-stage biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, today announces that a first patient has been treated in its phase I clinical trial (EV 2101) evaluating Oncobax® AK in lung and kidney cancer patients. The aim of the trial is to assess the […]

Access the press release

 

Our news

News
24/08/2023
Alliance Promotion Microbiote applauds the new legislation securing stool collection in France
> READ
Events
19/01/2023
Microbiota & Health Day 2023
> READ
News
26/04/2023
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
> READ
> See all news